Avsnitt

  • Episode #1: Amylin Pharmaceuticals

    Episode #1: Amylin Pharmaceuticals

    · Approved

    Listen on Spotify

    Listen on Apple Podcasts

    Listen on YouTube

    TABLE OF CONTENTS

    (00:00:00) - Introduction

    (00:04:40) - $50 of Dried Lizard Venom

    (00:29:17) - Fax of Death

    (00:43:04) - Sleeping Beauty Awakens

    (00:52:07) - Carl Icahn Sends a Letter

    (01:09:19) - Endgame

    (01:13:40) - Postmortem & Playbook

    CREDITS

    Co-hosted by Alex Kesin and Matthew Pech

    Written, edited, and produced by Alex Kesin

    Music: “Food” by nerowski

    * Special thanks to the team at NFX for the use of their recording studio.

    SOURCES

    Last updated: January 2026

    I. PRIMARY DOCUMENTS

    FDA Regulatory Documents

    Symlin (pramlintide acetate) - NDA 21-332

    * Approval Letter & Package (March 16, 2005)

    * Medical Review

    * Statistical Review

    * Clinical Pharmacology & Biopharmaceutics Review

    * Administrative Documents & Correspondence

    Byetta (exenatide) - NDA 21-773

    * Approval Letter & Package (April 28, 2005)

    * Medical Review

    * Statistical Review

    * Clinical Pharmacology & Biopharmaceutics Review

    * Administrative Documents & Correspondence

    Bydureon (exenatide ER) - NDA 22-200

    * Approval Letter (January 27, 2012)

    * Other Action Letters (Complete Response)

    * Summary Review

    * REMS

    * Administrative Correspondence

    SEC Filings & Financial Documents

    * Amylin 2005 Results Press Release (Ex-99.1, 8-K)

    * Amylin 2007 Results Press Release (Ex-99.1)

    * Amylin 2011 Form 10-K (Net Product Sales)

    * Carl Icahn SEC Filing (Schedule 13D)

    Proxy Fight & Legal Documents

    * Carl Icahn Letter to Amylin (April 15, 2009)

    * Amylin Response to Icahn (April 20, 2009)

    * Police Fund v. Bradbury (Amylin) Trial (May 4, 2009)

    * Lilly Litigation Ruling (May 25, 2011)

    II. ORAL HISTORY & INTERVIEWS

    * Howard Greene Oral History (UCSD Library, October 8, 2008) - Primary source for Hybritech founding, Ted Greene’s background, and early Amylin history

    III. NEWS & TRADE PRESS

    2000

    * “The Rumsfeld Resume” - CBS News (December 28, 2000) - Donald Rumsfeld’s board tenure at Amylin (1991-1996)

    * “Roller Coasting” - Forbes (July 24, 2000) - Joe Cook narrative, J&J partnership collapse

    2005

    * “Investing for a Profit and a Daughter’s Health” - NYT (March 19, 2005) - Allen Andersson investment story, “tablecloth deal”

    2006

    * “Diabetics see hope (and weight loss) in new drug” - NYT (March 2, 2006) - “Lizzie” nickname, patient testimonials

    * “4 Diabetes Drugs Are Seen Raising Hope and Profit” - NYT (June 22, 2006) - Manufacturing shortage, 400,000+ patients

    * “Don’t kill off life-saving drugs” - Heritage Foundation (August 15, 2006) - Policy perspective on Byetta’s potential impact

    * “Byetta Craze Is First Salvo in Promising New Line of Drugs” - diaTribe - ADA conference chaos, “one man cried”

    2007

    * Dr. John Eng Profile - Diabetes In Control (September 18, 2007) - Eng’s discovery story, patent struggles, Amylin vs. Lilly negotiations

    2008

    * Xenome/Amylin Partnership - BioSpace (February 5, 2008) - Venom peptide library partnership

    2009

    * Eastbourne Capital Sells Stake - San Diego Union-Tribune (October 10, 2009) - End of Eastbourne activist campaign

    * Survey: Additional Diabetes Drugs Needed - Cardiovascular Business (December 21, 2009) - Market research on GLP-1 adoption

    2012

    * “FDA review accuses Amylin of withholding data” - FierceBiotech (June 26, 2012) - Bydureon approval controversy

    IV. ACADEMIC & SCIENTIFIC SOURCES

    * “Structural insights into multiplexed pharmacological actions of tirzepatide...” - Nature Communications (February 25, 2022) - Tirzepatide structure, exenatide C-terminus connection

    * “Structural and dynamic features of cagrilintide binding...” - Nature Communications (April 10, 2025) - Cagrilintide/pramlintide structural relationship

    * “If You Poison Us Do We Not Die?” - BYU Law Review (May 1, 2010) - Legal analysis of poison put provisions

    * “How GLP-1 Receptor Agonists Evolved from Diabetes to Weight Loss Treatments” - Historical overview of GLP-1 development

    V. HARVARD BUSINESS SCHOOL CASES

    * “Amylin Pharmaceuticals: Diabetes and Beyond” (December 9, 2008) - Authors: Richard G. Hamermesh, Rachel Gordon

    * “Amylin Pharmaceuticals: Diabetes and Beyond” (November 2, 2012 revision) - Authors: Richard G. Hamermesh, Carin-Isabel Knoop

    VI. CORPORATE DOCUMENTS & PRESENTATIONS

    Amylin investor presentations from corporate IR archives. Specific slides referenced in the script are noted below.

    Investor Presentations (Full Decks)

    * 2006 R&D Day Presentation (PDF) - Phybrids platform, GIP mimetic program (slides 43, 46, 58-59)

    * 2007 R&D Day Presentation (PDF) - Market sizing, obesity portfolio positioning (slides 14, 28, 29, 78)

    * 2007 J.P. Morgan Healthcare Conference (PDF) - Symlin Pen timeline (slide 25)

    * 2007 Lehman Brothers Healthcare Conference (PDF) - Investor overview and pipeline update

    Individual Slide Presentations (HTML Archives)

    * Early Corporate Presentation (WFVK) - Early-era company overview

    * 2003 Headquarters Presentation - January 2003 corporate update

    * ADA IR Presentation - American Diabetes Association investor materials

    VII. ADDITIONAL REFERENCES

    * Encyclopedia.com: Amylin Pharmaceuticals, Inc.

    * Miami Serpentarium Laboratories (Gila monster venom source)

    * Dan Bradbury (former Amylin CEO) - Vivani Board Profile - Now developing exenatide implant for weight loss

    * Full-year 2008 results - FierceBiotech

    VIII. PRIMARY SOURCE FIGURES

    IX. ANALYSIS FIGURES



    This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.approved.fm

  • Saknas det avsnitt?

    Klicka här för att uppdatera flödet manuellt.